Femasys Inc.
FEMY Healthcare Medical Instruments & Supplies
Femasys Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.3 million, up 40.8% from fiscal 2024. In the quarter to June 2026, revenue fell 18.9%, EPS grew 58.4%, free cash flow grew 11.3% and total debt rose 3,369.3%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
Follow FEMY
Femasys Inc. (FEMY) EV/Sales
As of 16 October 2026, Femasys Inc. (FEMY) trades at a EV/Sales of 3.4×. Over the past ten years it has ranged from −12.9× (September 2021) to 60.8× (June 2021); the current reading is higher than 37% of that period. That is above the Medical Instruments & Supplies industry median of 2.9× and in line with the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 8.2× | (36.88%) |
| FY2024 | 13.0× | — |
| FY2023 | −1.7× | — |
| FY2022 | −1.8× | — |
| FY2021 | 1.3× | (97.82%) |
| FY2020 | 60.8× | 0.00% |
| FY2020 | 60.8× | 0.00% |
| FY2019 | 60.8× | 0.00% |
| FY2019 | 60.8× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 7.0× | (36.86%) |
| Mar 2026 | 11.2× | 36.09% |
| Dec 2025 | 8.2× | 69.56% |
| Sep 2025 | 4.8× | (63.17%) |
| 22 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| RVP Retractable Technologies, Inc. compare | −0.6× |
| RGNT Regentis Biomaterials Ltd. compare | n/m |
| CUPR Cuprina Holdings (Cayman) Limited compare | n/m |
| LUCY Innovative Eyewear, Inc. compare | 0.4× |
| BNGO Bionano Genomics, Inc. compare | 0.7× |
| HBIO Harvard Bioscience, Inc. compare | 1.1× |
| MLSS Milestone Scientific, Inc. compare | 3.1× |
| FEMY Femasys Inc. | 3.4× |
| NXGL NexGel, Inc. compare | 4.3× |
| Medical Instruments & Supplies industry median | 2.9× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)